495 related articles for article (PubMed ID: 25402820)
1. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
[TBL] [Abstract][Full Text] [Related]
2. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
Zhang Y; Liu L; Fan P; Bauer N; Gladkich J; Ryschich E; Bazhin AV; Giese NA; Strobel O; Hackert T; Hinz U; Gross W; Fortunato F; Herr I
Oncotarget; 2015 Apr; 6(12):9999-10015. PubMed ID: 25846752
[TBL] [Abstract][Full Text] [Related]
3. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Rajeshkumar NV; Rasheed ZA; García-García E; López-Ríos F; Fujiwara K; Matsui WH; Hidalgo M
Mol Cancer Ther; 2010 Sep; 9(9):2582-92. PubMed ID: 20660600
[TBL] [Abstract][Full Text] [Related]
4. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.
Shimamura T; Royal RE; Kioi M; Nakajima A; Husain SR; Puri RK
Cancer Res; 2007 Oct; 67(20):9903-12. PubMed ID: 17942922
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells.
Matsuzawa F; Kamachi H; Mizukami T; Einama T; Kawamata F; Fujii Y; Fukai M; Kobayashi N; Hatanaka Y; Taketomi A
BMC Cancer; 2021 Feb; 21(1):200. PubMed ID: 33637083
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype.
Hu G; Li F; Ouyang K; Xie F; Tang X; Wang K; Han S; Jiang Z; Zhu M; Wen D; Qin X; Zhang L
Int J Oncol; 2012 Mar; 40(3):798-806. PubMed ID: 22076649
[TBL] [Abstract][Full Text] [Related]
8. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
Zhuang Z; Li H; Lee H; Aguilar M; Gocho T; Ju H; Iida T; Ling J; Fu J; Wu M; Sun Y; Lu Y; Chiao PJ
Cancer Lett; 2017 Dec; 411():44-56. PubMed ID: 28951128
[TBL] [Abstract][Full Text] [Related]
9. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
[TBL] [Abstract][Full Text] [Related]
10. Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer.
Li J; Wang R; Schweickert PG; Karki A; Yang Y; Kong Y; Ahmad N; Konieczny SF; Liu X
Cell Cycle; 2016; 15(5):711-9. PubMed ID: 26890815
[TBL] [Abstract][Full Text] [Related]
11. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.
Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
Mol Cancer Ther; 2012 Dec; 11(12):2644-53. PubMed ID: 23047891
[TBL] [Abstract][Full Text] [Related]
12. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
Yoshida K; Toden S; Ravindranathan P; Han H; Goel A
Carcinogenesis; 2017 Oct; 38(10):1036-1046. PubMed ID: 29048549
[TBL] [Abstract][Full Text] [Related]
13. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
[TBL] [Abstract][Full Text] [Related]
14. The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine.
Jung DB; Yun M; Kim EO; Kim J; Kim B; Jung JH; Wang E; Mukhopadhyay D; Hammond E; Dredge K; Shridhar V; Kim SH
Oncotarget; 2015 Mar; 6(7):4992-5004. PubMed ID: 25669977
[TBL] [Abstract][Full Text] [Related]
15. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
[TBL] [Abstract][Full Text] [Related]
16. Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts.
Hermann PC; Trabulo SM; Sainz B; Balic A; Garcia E; Hahn SA; Vandana M; Sahoo SK; Tunici P; Bakker A; Hidalgo M; Heeschen C
PLoS One; 2013; 8(6):e66371. PubMed ID: 23825539
[TBL] [Abstract][Full Text] [Related]
17. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
18. Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.
Daylami R; Muilenburg DJ; Virudachalam S; Bold RJ
J Exp Clin Cancer Res; 2014 Dec; 33(1):102. PubMed ID: 25499121
[TBL] [Abstract][Full Text] [Related]
19. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.
Frese KK; Neesse A; Cook N; Bapiro TE; Lolkema MP; Jodrell DI; Tuveson DA
Cancer Discov; 2012 Mar; 2(3):260-269. PubMed ID: 22585996
[TBL] [Abstract][Full Text] [Related]
20. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.
Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
Int J Cancer; 2012 Aug; 131(3):E292-303. PubMed ID: 21935918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]